vs
Esperion Therapeutics, Inc.（ESPR）与IPG PHOTONICS CORP（IPGP）财务数据对比。点击上方公司名可切换其他公司
IPG PHOTONICS CORP的季度营收约是Esperion Therapeutics, Inc.的1.6倍（$274.5M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 17.1%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 4.4%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
IPG光电是全球领先的光纤激光器制造商，率先实现光纤激光器的技术研发与商业化落地，产品广泛应用于材料加工、医疗、电信等多元领域，在美国、德国、俄罗斯、意大利均设有生产基地，为全球各行业客户提供高性能的激光解决方案。
ESPR vs IPGP — 直观对比
营收规模更大
IPGP
是对方的1.6倍
$168.4M
营收增速更快
ESPR
高出126.6%
17.1%
两年增速更快
ESPR
近两年复合增速
4.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $274.5M |
| 净利润 | — | $13.3M |
| 毛利率 | — | 36.1% |
| 营业利润率 | 50.6% | 1.2% |
| 净利率 | — | 4.8% |
| 营收同比 | 143.7% | 17.1% |
| 净利润同比 | — | 69.8% |
| 每股收益（稀释后） | $0.32 | $0.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRIPGP
| Q4 25 | $168.4M | $274.5M | ||
| Q3 25 | $87.3M | $250.8M | ||
| Q2 25 | $82.4M | $250.7M | ||
| Q1 25 | $65.0M | $227.8M | ||
| Q4 24 | $69.1M | $234.3M | ||
| Q3 24 | $51.6M | $233.1M | ||
| Q2 24 | $73.8M | $257.6M | ||
| Q1 24 | $137.7M | $252.0M |
净利润ESPRIPGP
| Q4 25 | — | $13.3M | ||
| Q3 25 | $-31.3M | $7.5M | ||
| Q2 25 | $-12.7M | $6.6M | ||
| Q1 25 | $-40.5M | $3.8M | ||
| Q4 24 | — | $7.8M | ||
| Q3 24 | $-29.5M | $-233.6M | ||
| Q2 24 | $-61.9M | $20.2M | ||
| Q1 24 | $61.0M | $24.1M |
毛利率ESPRIPGP
| Q4 25 | — | 36.1% | ||
| Q3 25 | — | 39.5% | ||
| Q2 25 | — | 37.3% | ||
| Q1 25 | — | 39.4% | ||
| Q4 24 | — | 38.6% | ||
| Q3 24 | — | 23.2% | ||
| Q2 24 | — | 37.3% | ||
| Q1 24 | — | 38.7% |
营业利润率ESPRIPGP
| Q4 25 | 50.6% | 1.2% | ||
| Q3 25 | -11.4% | 3.1% | ||
| Q2 25 | 8.6% | 0.0% | ||
| Q1 25 | -34.0% | 0.8% | ||
| Q4 24 | -6.4% | 6.0% | ||
| Q3 24 | -31.0% | -108.7% | ||
| Q2 24 | 3.5% | 4.7% | ||
| Q1 24 | 52.5% | 7.6% |
净利率ESPRIPGP
| Q4 25 | — | 4.8% | ||
| Q3 25 | -35.9% | 3.0% | ||
| Q2 25 | -15.4% | 2.6% | ||
| Q1 25 | -62.2% | 1.6% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | -57.2% | -100.2% | ||
| Q2 24 | -83.9% | 7.8% | ||
| Q1 24 | 44.3% | 9.6% |
每股收益（稀释后）ESPRIPGP
| Q4 25 | $0.32 | $0.30 | ||
| Q3 25 | $-0.16 | $0.18 | ||
| Q2 25 | $-0.06 | $0.16 | ||
| Q1 25 | $-0.21 | $0.09 | ||
| Q4 24 | $-0.14 | $0.27 | ||
| Q3 24 | $-0.15 | $-5.33 | ||
| Q2 24 | $-0.33 | $0.45 | ||
| Q1 24 | $0.34 | $0.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $839.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $2.1B |
| 总资产 | $465.9M | $2.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRIPGP
| Q4 25 | $167.9M | $839.3M | ||
| Q3 25 | $92.4M | $870.4M | ||
| Q2 25 | $86.1M | $899.6M | ||
| Q1 25 | $114.6M | $926.9M | ||
| Q4 24 | $144.8M | $930.2M | ||
| Q3 24 | $144.7M | $1.0B | ||
| Q2 24 | $189.3M | $1.1B | ||
| Q1 24 | $226.6M | $1.1B |
股东权益ESPRIPGP
| Q4 25 | $-302.0M | $2.1B | ||
| Q3 25 | $-451.4M | $2.1B | ||
| Q2 25 | $-433.5M | $2.1B | ||
| Q1 25 | $-426.2M | $2.1B | ||
| Q4 24 | $-388.7M | $2.0B | ||
| Q3 24 | $-370.2M | $2.1B | ||
| Q2 24 | $-344.2M | $2.3B | ||
| Q1 24 | $-294.3M | $2.3B |
总资产ESPRIPGP
| Q4 25 | $465.9M | $2.4B | ||
| Q3 25 | $364.0M | $2.4B | ||
| Q2 25 | $347.1M | $2.4B | ||
| Q1 25 | $324.0M | $2.3B | ||
| Q4 24 | $343.8M | $2.3B | ||
| Q3 24 | $314.1M | $2.4B | ||
| Q2 24 | $352.3M | $2.5B | ||
| Q1 24 | $373.1M | $2.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $28.8M |
| 自由现金流经营现金流 - 资本支出 | — | $10.9M |
| 自由现金流率自由现金流/营收 | — | 4.0% |
| 资本支出强度资本支出/营收 | 0.0% | 6.5% |
| 现金转化率经营现金流/净利润 | — | 2.17× |
| 过去12个月自由现金流最近4个季度 | — | $-3.5M |
8季度趋势，按日历期对齐
经营现金流ESPRIPGP
| Q4 25 | $45.2M | $28.8M | ||
| Q3 25 | $-4.3M | $35.3M | ||
| Q2 25 | $-31.4M | $-2.2M | ||
| Q1 25 | $-22.6M | $13.4M | ||
| Q4 24 | $-35.0M | $73.8M | ||
| Q3 24 | $-35.3M | $66.1M | ||
| Q2 24 | $-7.2M | $53.5M | ||
| Q1 24 | $53.8M | $54.6M |
自由现金流ESPRIPGP
| Q4 25 | — | $10.9M | ||
| Q3 25 | — | $14.6M | ||
| Q2 25 | — | $-17.6M | ||
| Q1 25 | — | $-11.4M | ||
| Q4 24 | — | $50.6M | ||
| Q3 24 | $-35.5M | $43.0M | ||
| Q2 24 | $-7.3M | $29.2M | ||
| Q1 24 | $53.8M | $26.5M |
自由现金流率ESPRIPGP
| Q4 25 | — | 4.0% | ||
| Q3 25 | — | 5.8% | ||
| Q2 25 | — | -7.0% | ||
| Q1 25 | — | -5.0% | ||
| Q4 24 | — | 21.6% | ||
| Q3 24 | -68.7% | 18.4% | ||
| Q2 24 | -9.9% | 11.3% | ||
| Q1 24 | 39.0% | 10.5% |
资本支出强度ESPRIPGP
| Q4 25 | 0.0% | 6.5% | ||
| Q3 25 | 0.0% | 8.3% | ||
| Q2 25 | 0.0% | 6.1% | ||
| Q1 25 | 0.0% | 10.9% | ||
| Q4 24 | 0.0% | 9.9% | ||
| Q3 24 | 0.3% | 9.9% | ||
| Q2 24 | 0.1% | 9.4% | ||
| Q1 24 | 0.1% | 11.1% |
现金转化率ESPRIPGP
| Q4 25 | — | 2.17× | ||
| Q3 25 | — | 4.73× | ||
| Q2 25 | — | -0.34× | ||
| Q1 25 | — | 3.58× | ||
| Q4 24 | — | 9.44× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.65× | ||
| Q1 24 | 0.88× | 2.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
IPGP
| Materials Processing | $232.8M | 85% |
| Laser And Non Laser Systems | $38.8M | 14% |
| Transferred Over Time | $5.3M | 2% |
